The ALXN1210 results this morning are a "clear success" for Alexion Pharmaceuticals given an already high efficacy bar for Soliris as well as lingering concerns about an increased risk for meningococcal infection with the drug, which did not materialize, Deutsche Bank analyst Andrew Peters tells investors in a research note. The analyst adds that although ALXN1210 did not meet statistical superiority across any single endpoint, the consistent trends suggesting numerical superiority across all endpoints and a very narrow miss on superiority for breakthrough hemolysis support that the drug not only offers increased convenience and quality of life by reducing transfusion frequency but also potentially offers improved efficacy. Peters reiterates a Buy rating on shares of Alexion with a $161 price target.